Neglected and underrepresented subpopulations: Elderly and performance status 2 patients with advanced-stage non-small-cell lung cancer

Clinical Lung Cancer

Volumn 7, Issue SUPPL. 4, 2006, Pages

  Langer, Corey J ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Combination chemotherapy; Gemcitabine; Paclitaxel poliglumex; Single agent therapy; Therapeutic challenge; Vinorelbine

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; NAVELBINE; PACLITAXEL; PACLITAXEL DERIVATIVE; PACLITAXEL POLIGLUMEX; PEMETREXED; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG;

ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL STUDY; CLINICAL TRIAL; COMORBIDITY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG TARGETING; FEBRILE NEUTROPENIA; FUNCTIONAL STATUS; GERIATRIC CARE; GERIATRIC PATIENT; HEMOPTYSIS; HUMAN; HYPOTENSION; INTERSTITIAL LUNG DISEASE; LEUKEMIA; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; META ANALYSIS; MONOTHERAPY; MYALGIA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PSYCHOPATHY; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; STOMATITIS; SURVIVAL TIME; SYSTEMATIC REVIEW; TUMOR VOLUME; WEIGHT REDUCTION;

EID: 33745940356     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2006.s.004     Document Type: Article

References (67)

1. Johnson DH. Chemotherapy for metastatic non-small cell lung cancer. J Natl Cancer Inst 1993; 85:766-767.
2. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data in individual patients from 52 randomized clinical trials. BMJ 1995; 311:899-909.
3. Jiroutek M, Johnson D, Blum P, et al. Prognostic factors in advanced NSCLC: analysis of ECOG trials from 1981-1992. Proc Am Soc Clin Oncol 1998; 17:461a (Abstract #1774).
4. Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 9:1618-1626.
5. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997; 80:1273-1283.
6. US Census Bureau. US interim projections by age, race, sex and Hispanic origin. Available at: http://www.census.gov/ipc/www/usinterimproj. Accessed March 31, 2006.
7. Yellen SB, Celia DF, Leslie WT. Age and clinical decision making in oncology patients. J Natl Cancer Inst 1994; 86:1766-1770.
8. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age and older in cancer-treatment trials. N Engl J Med 1999; 341:2061-2067.
9. Langer CJ, Manola J, Bernado P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002; 94:173-181.
10. Langer CJ, Vangel M, Schiller J, et al. Age-specific subanalysis of ECOG 1594: fit elderly patients (70-80 yrs) with NSCLC do as well as younger patients (<70). Proc Am Soc Clin Oncol 2003; 22:639 (Abstract #2571).
11. Kelly K, Giarritta S, Akerley W, et al. Should older patients (Pts) receive combination chemotherapy for advanced stage non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology trials 9509 and 9308. Proc Am Soc Clin Oncol 2001; 20:329s (Abstract #1313).
12. Lilenbaum RC, Herndon JE II, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer. The Cancer and Leukemia Group B (study 9730). J Clin Oncol 2005; 23:190-196.
13. Hensing TA, Peterman AH, Schell MJ, et al. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 2003; 98:779-788.
14. Smith TJ, Penberthy L, Desch CE, et al. Differences in initial treatment patterns and outcomes of lung cancer in the elderly. Lung Cancer 1995; 13:235-252.
15. Wingo PA, Cardinez CJ, Landis SH, et al. Long term trends in cancer mortality in the United States, 1930-1998. Cancer 2003; 97(suppl 12):3133-3275.
16. Weinmann M, Jeremic B, Toomes H, et al. Treatment of lung cancer in the elderly. Part I: non-small cell lung cancer. Lung Cancer 2003; 39:233-253.
17. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91:66-72.
18. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18:2529-2536.
19. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95:362-372.
20. Frasci C, on behalf of the Southern Italy Cooperative Ontology Group (SICOG). Chemotherapy of lung cancer in the elderly. Crit Rev Oncol Hematol 2002; 41:349-361.
21. Perrone F, Gridelli C, Cigolari S, et al. Baseline assessment of quality of life (QOL) is a strong prognostic factor for survival of elderly patients with advanced non-small cell lung cancer (NSCLC). A secondary analysis of the MILES study. Proc Am Soc Clin Oncol 2002; 21:337a (Abstract # 1346).
22. Takeda K, Kudoh S, Nakagawa K, et al. Randomized phase III study of docetaxel (D) versus vinorelbine (V) for elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): results of a West Japan Thoracic Oncology Group trial (WJTOG9904). J Clin Oncol 2005; 23(16 suppl):623s (Abstract #7009).
23. Hesketh PJ, Chansky K, Lau DH, et al, for the Southwest Oncology Group. Sequential vinorelbine (V) and docetaxel (D) in advanced non-small cell lung cancer (NSCLC) patients age > 70, or with performance status (PS) 2: a SWOG phase II trial (S0027). J Clin Oncol 2004; 22:627 (Abstract #7056).
24. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced nonsmall-cell lung cancer the TAX 326 study group. J Clin Oncol 2003; 22:3016-3024.
25. Fossella F, Belani C, for the TAX 326 Study Group. Phase III study (TAX 326) of docetaxel-cisplatin (DC) and docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) for the first-line treatment of advanced/ metastatic non-small-cell-lung cancer (NSCLC): analysis in elderly patients. Proc Am Soc Clin Oncol 2003; 22:629 (Abstract #2528).
26. Belani CP, Barstis J, Perry M, et al. Multicenter, randomzied trial for stage IIIB and IV non-small cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003; 22:2933-2939.
27. Ramalingam S, Belani CP, Barstis J, et al. Treatment of elderly non-small cell lung cancer (NSCLC) patients with three different schedules of weekly paclitaxel in combination with carboplatin: subanalysis of a randomized trial. Proc Am Soc Clin Oncol 2003; 22:670 (Abstract #2693).
28. Belani CP, Larocca RV, Rinaldi DA, et al. A multicenter, phase III randomized trial for stage IIIB/IV NSCLC of weekly paclitaxel and carboplatin vs. standard paclitaxel and carboplatin given every three weeks, followed by weekly paclitaxel. Proc Am Soc Clin Oncol 2004; 23:619 (Abstract #7017).
29. Belani CP, Ramalingam S, Perry M, et al. Phase III randomized trial comparing weekly vs standard schedule of paclitaxel and carboplatin for advanced non-small cell lung cancer. Presented at: 11th World Conference on Lung Cancer of the International Association for the Study of Lung Cancer (IASLC); July 3-6, 2005; Barcelona, Spain. Abstract #1083.
30. Mainwaring MG, Hainsworth JD, Spigel DR, et al. Weekly docetaxel versus weekly docetaxel/gemcitabine as first-line therapy for patients who are elderly or with poor performance status (PS) or with serious comorbidities with advanced non-small cell lung cancer (NSCLC): interim safety analysis of a Minnie Pearl Cancer Research Network phase III trial. J Clin Oncol 2005; 23(16 suppl):658s (Abstract #7151).
31. Hainsworth JD, Carrell D, Drengler RL, et al. Weekly combination chemotherapy with codetaxel and gemcitabine as first line treatment for elderly patients and patients with poor performance status who have extensive-stage small cell lung carcinoma: a Minnie Pearl Cancer Research Network phase II trial. Cancer 2004; 100:2437-2441.
32. Gridelli C, Reck M, Gregorc V, et al. Single-agent pemetrexed or sequentially administered pemetrexed/gemcitabine as first-line chemotherapy for advanced non-small cell lung cancer (NSCLC) in elderly patients or patients ineligible for platinum-based chemotherapy: preliminary results of a phase II randomized trial. J Clin Oncol 2005; 23(16 suppl):659s (Abstract #7156).
33. Ohe Y, Niho S, Kakinuma R, et al. A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients. Ann Oncol 2004; 15:45-50.
34. Gridelli C, Maione P, Castaldo V, et al. Gefitinib in elderly and unfit patients affected by advanced non-small cell lung cancer. Br J Cancer 2003; 89:1827-1829.
35. Soto Parra H, Cavina R, Zucali P, et al. Gefitinib in elderly patients with progressive, pretreated, non small cell lung cancer: results from the Istituto Clinico Humanitas. Br J Cancer 2003; 89:S25-S35.
36. Stahel R, Rossi A, Petruzelka L, et al. Lessons from the Iressa Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations. Br J Cancer 2003; 89:S19-S23.
37. Cappuzzo F, Bartolini S, Ceresoli G, et al. Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). Br J Cancer 2004; 90:82-86.
38. Scagliotti G, Rossi A, Novello S, et al. Gefitinib (ZD1839) combined with gemcitabine or vinorelbine as single-agent in elderly patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 23:633 (Abstract #7081).
39. Shepherd FA. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC). Proc Am Soc Clin Oncol 2004; 23:622s (Abstract #7022).
40. Johnson B, Lucca J, Rabin M, et al. A phase II trial of erlotinib in previously untreated elderly patients (>70 years) with advanced NSCLC. Preliminary results. Ann Oncol 2004; 15 (suppl 3):169 (Abstract #639PD).
41. Johnson DH. Chemotherapy for metastatic non-small cell lung cancer. J Natl Cancer Inst 1993; 85:766-767.
42. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data in individual patients from 52 randomized clinical trials. BMJ 1995; 11:899-909.
43. Cella D. Quality of life considerations in patients with advanced lung cancer. Semin Oncol 2004; 31(6 suppl 11): 16-20.
44. Ruckdeschel JC, Finkelstein DM, Ettinger DS, et al. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 1986; 4:14-22.
45. Alberola V, Camps C, Provencio M, et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 2003; 21:3207-3213.
46. Van Meerbeeck JP, Smit EF, Lianes P, et al. A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20:308 (Abstract #1228).
47. Sweeney C, Zhu J, Sandler AB, et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase III trial in patients with metastatic non-small cell lung carcinoma. Cancer 2001; 92:2639.
48. Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 1999; 17:12-18.
49. Crino L, Scagliotti G, Marangolo M, et al. Cisplatin-gemcitabine combination in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 1997; 15:297-303.
50. Rinaldi M, Crino L, Scagliotti G, et al. A new schedule of gemcitabine-cisplatin in advanced non-small cell lung cancer with two different cisplatin dose levels: a phase II randomized trial. Proc Am Soc Clin Oncol 1998; 17:470a (Abstract #1807).
51. Langer C, Stephenson P, Schiller J, et al. ECOG 1599: randomized phase II study of paclitaxel/carboplatin vs cisplatin/gemcitabine in performance status (PS) 2 patients with treatment-naïve advanced NSCLC. Lung Cancer 2003; 41 (suppl 2):S18 (Abstract O-52).
52. Lilenbaum RC, Herndon J, List M, et al. Single-agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): a CALGB randomized trial of efficacy, quality of life (QOL), and cost-effectiveness. Proc Am Soc Clin Oncol 2002; 21:a1 (Abstract #2).
53. Kosimidis PA, Dimopoulos MA, Syrigos C, et al. Gemcitabine (G) vs gemcitabine-carboplatin (GCB) for patients with advanced non-small cell lung cancer (NSCLC) and PS:2. A prospective randomized phase II study of the Hellenic Co-Operative Oncology Group. Proc Am Soc Clin Oncol 2004; 23:627 (Abstract #7058).
54. Li C, Newman RA, Wu QP, et al. Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian Oca-1 tumor. Cancer Chemother Pharmacol 2000; 46:416-422.
55. Vasey PA, Kaye SB, Morrison R, et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin Cancer Res 1999; 5:83-94.
56. Rose WC, Clark JL, Lee FWF, et al. Pre-clinical anti-tumor activity water-soluble paclitaxel derivatives. Cancer Chemother Pharmacol 1997; 39:486-492.
57. Singer JW, Baker B, De Vries P, et al. Poly-(L)-glutamic acid-paclitaxel (CT-2103) [Xyotax], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. Adv Exp Med Biol 2003; 519:81-99.
58. Li C, Yu DF, Newman RA, et al. Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate. Cancer Res 1998; 58:2404-2409.
59. Li C, Price JE, Milas L, et al. Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors. Clin Cancer Res 1999; 5:891-897.
60. Burris H, Shipley D, Greco A, et al. Phase 1 studies of CT-2103 in patients with non small cell lung cancer and with advanced malignancies. Eur J Cancer Suppl 2003; 1: S168 (Abstract #555).
61. Verrill MW, Buddy AV, Todd R, et al. Phase 1 pharmacokinetic study of CT-2103 given Q2 or Q3 weeks in patients with solid tumors. Proc Am Soc Clin Oncol 2003; 22:133 (Abstact #533).
62. Sabbatini P, Brown J, Peters WA, et al. Phase I/II study of CT-2103 (Xyotax) in patients with recurrent ovarian cancer. Eur J Cancer 2002; 38(suppl 7):130 (Abstract #430).
63. Skubitz K, Kudelka A, Bolton MG. Phase 1 study of CT-2103/cisplatin in patients with solid tumors. Eur J Cancer Suppl 2003; 1:S168 (Abstract #554).
64. Nemunaitis J, Garzone P, Bolton MG. Phase I study of Xyotax (CT-2103) and carboplatin in patients with solid tumors: preliminary data. Eur J Cancer 2002; 38(suppl 7):132 (Abstract #438).
65. Bodkin D, Neubauer M, Bolton MG. Phase 2 study of first line chemotherapy using CT-2103 (Xyotax) in patients with non-small-cell lung cancer who are >69 years of age or who have performance status (PS) = 2. Eur J Cancer Suppl 2003; 1:S242 (Abstract #806).
66. Langer CP, O'Byrne K, Ross H, et al. Xyotax/carbopolatin vs paclitaxel/ carboplatin for the treatment of PS2 patients with chemotherapy-naive advanced non-small cell lung cancer (NSCLC): the Stellar 3 phase III study. Lung Cancer 2005; 49(suppl 2): S36 (Abstract O-101).
67. O'Brien M, Sandler A, Popovish A, et al. Xyotax vs. gemcitabine or vinorelbine for the treatment of performance status (PS) 2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): the STELLAR 4 phase III study. Lung Cancer 2005; 49(suppl 2):S37 (Abstract O-104).